HCP Pivotal Trial Results

Now you can have your patients GO BIONIC

The Bionic Pancreas Pivotal Trial is the largest randomized controlled trial evaluating the safety and efficacy of an AID system1

Primary outcome

• HbA1c at 13 weeks vs Standard of Care

Key secondary outcome

• Time CGM glucose < 54 mg/dl over 13 weeks vs Standard of Care

Other secondary end points

• Mean CGM

• Time in Range

Number of patients included in trial – 440

• iLet Bionic Pancreas (Humalog/Novolog and Fiasp) – 333

• Standard of Care – 107

74%

White (Non-Hispanic)

10%

Hispanic

10%

Black (Non-Hispanic)

6%

Other or more than one race

Diabetes doesn’t discriminate

Our pivotal study participant population was more diverse and representative of the US T1D community than any other pivotal trial of an AID system2-7

Nearly 2/3 had a baseline
HbA1c >7.5%

Insulin Delivery

• Insulin delivery: ≥33% MDI

• Insulin pump without automation: 31%

• Insulin pump with automation: 35%

• Control IQ (23%)

• 670G (8%)

• Predictive Low Glucose Suspend Devices (4%)

No Exclusions for

• Hypoglycemic unawareness

• Recent episodes of severe hypoglycemia

• Recent episodes of DKA

• Recent hospitalization for dysglycemia

• Baseline HbA1c

1. Brown, S. A. et al. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care 44, dc210172 (2021). 2. Breton, M. D. et al. A Randomized Trial of Closed- Loop Control in Children with Type 1 Diabetes. New Engl J Med 383, 836–845 (2020). 3. Brown, S. A. et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. New Engl J Med 381, 1707–1717 (2019). 4. https://www.accessdata.fda.gov/cdrh_docs/ pdf16/p160017b.pdf. 5. Russell, S.J., et al. (2022) A Multicenter Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. The New England Journal of Medicine. 387:1161–1172.. 6. Lawrence, J. M. et al. Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017. JAMA 326, 717–727 (2021).

The iLet Bionic Pancreas improved HbA1c more in those with a baseline HbA1c of >7%

The study was not designed to evaluate the effect of the iLet Bionic Pancreas in subgroups by baseline HbA1c. Individual user results may vary from the average values shown here.

1. Kruger, D,. et. Al. (2022) A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics 2022; 24:697–711. 2. Messer, L.H., et al.(2022) Positive impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial. Diabetes Technology and Therapeutics 2022; 24:712–725.

By using the iLet Bionic Pancreas, your patients, on average, can have nearly 1,000 more hours Time in Range each year 1

Ready to GO BIONIC?

The iLet Bionic Pancreas automatically adjusts to your insulin needs so you don’t have to.

GO BIONIC

MM000055_A

Beta Bionics is a public benefit corporation.

We are committed to balancing purpose with profit and giving back to society as we fulfill our public benefit mission.

Safety Information – The iLet Bionic Pancreas System is indicated for use by people with type 1 diabetes 6 years of age and older. The iLet Bionic Pancreas requires prescription by a physician. Refer to the iLet Bionic Pancreas System User Guide at www.betabionics.com/resouces/user-guides, or for complete safety information including indications, contraindications, warnings, cautions, compatible devices, compatible drugs and instructions, refer to www.betabionics.com/resources/safety. DO NOT start to use the iLet Bionic Pancreas System without adequate training. Incorrect use may result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.

Medical Disclaimer – This website is for information only and is not a substitute for medical advice and/or services from a healthcare provider. All personal health care decisions and treatment should be discussed with a healthcare provider who is familiar with your individual needs.

Copyright © 2024 Beta Bionics | Privacy Policy | Safety | Terms of Use | Cookies | Patents  | Code of Conduct